You are here

  • Home
  • Archive
  • Volume 76, Issue 11
  • Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Keystone EC, Taylor PC, Tanaka Y, et al
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Annals of the Rheumatic Diseases 2017;76:1853-1861.